These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23591780)

  • 21. Physiologically-based pharmacokinetics of ziprasidone in pregnant women.
    Biesdorf C; Martins FS; Sy SKB; Diniz A
    Br J Clin Pharmacol; 2019 May; 85(5):914-923. PubMed ID: 30669177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologically Based Pharmacokinetic Models Can Be Used to Predict the Unique Nonlinear Absorption Profiles of Vismodegib.
    Lin L; Wright MR; Hop CECA; Wong H
    Drug Metab Dispos; 2022 Sep; 50(9):1170-1181. PubMed ID: 35779865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
    Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
    Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
    Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
    Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Reproductive and Developmental Toxicity Profile of a Glycine Transporter Type 1 (Glyt1) Inhibitor.
    Barrow P; Parrott N; Alberati D; Paehler A; Koerner A
    Birth Defects Res B Dev Reprod Toxicol; 2016 Jun; 107(3):148-56. PubMed ID: 27221585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K
    Lee HA; Lee KR; Jang SB; Chung SY; Yu KS; Lee H
    Eur J Pharm Sci; 2019 Mar; 130():1-10. PubMed ID: 30641142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.
    Sinha VK; Vaarties K; De Buck SS; Fenu LA; Nijsen M; Gilissen RA; Sanderson W; Van Uytsel K; Hoeben E; Van Peer A; Mackie CE; Smit JW
    Clin Pharmacokinet; 2011 May; 50(5):307-18. PubMed ID: 21456631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds.
    Mao J; Ma F; Yu J; Bruyn T; Ning M; Bowman C; Chen Y
    Biopharm Drug Dispos; 2023 Aug; 44(4):315-334. PubMed ID: 37160730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: results of three clinical trials.
    Heinig R; Weimann B; Dietrich H; Böttcher MF
    Clin Drug Investig; 2011; 31(1):27-41. PubMed ID: 20925442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.
    Rhee SJ; Chung H; Yi S; Yu KS; Chung JY
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):973-980. PubMed ID: 28536774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition.
    Poulin P; Theil FP
    J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
    Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
    Poirier A; Cascais AC; Funk C; Lavé T
    Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
    Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
    AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling Age-Related Changes in the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Different CYP2D6 Phenotypes Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Hempel G
    Pharm Res; 2020 May; 37(6):110. PubMed ID: 32476097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.